Clinical trial
Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein
NCT00048880 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00048880 |
|---|---|
| Title | Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein |
| Official title | Phase I Study of HeFi-1 in Refractory CD30-Positive Malignancy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | HeFi-1 Monoclonal Antibody |
| Enrollment | 9 |
| Start date | Nov 5, 2002 |
| Primary completion | Jul 2, 2008 |
| Completion | Jul 2, 2008 |
| First posted | Nov 11, 2002 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: